Phase I/Ii Study Of The Oral Hif-2 Alpha Inhibitor Mk-6482 In Patients With Advanced Clear Cell Renal Cell Carcinoma (Rcc)

Toni K. Choueiri,Elizabeth R. Plimack,Todd Michael Bauer,Jaime R. Merchan,Kyriakos P. Papadopoulos,David F. McDermott,M Dror Michaelson,Leonard Joseph Appleman,Sanjay Thamake,Naseem J. Zojwalla,Eric Jonasch

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 5|浏览1

暂无评分

摘要

611Background: Hypoxia-inducible factor (HIF)-2α is a transcription factor that is a key oncogenic driver in RCC. MK-6482 is a first-in-class small molecule HIF-2α inhibitor that blocks the heterod...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要